Recently, promising therapeutic strategies such as cancer immunosuppressive therapy have improved clinical prognosis for patients with unresectable HCC; and the combination of ICIs and vascular endothelial growth factor inhibitor, Atezo + Bev combination therapy, is now positioned as the first‐line regimen.35 This evidence concerns the gene VEGFA and hepatocellular carcinoma.